![](/img/cover-not-exists.png)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients
Scagliotti, Giorgio, Moro-Sibilot, Denis, Kollmeier, Jens, Favaretto, Adolfo, Cho, Eun Kyung, Grosch, Heidrun, Kimmich, Martin, Girard, Nicolas, Tsai, Chun-Ming, Hsia, Te-Chun, Brighenti, Matteo, SchuLanguage:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2019.10.003
Date:
October, 2019
File:
PDF, 485 KB
english, 2019